澄天偉業(300689.SZ):部分已研發的功率半導體器件目前是給光伏逆變和儲能等場景的頭部企業送樣測試
格隆匯7月19日丨有投資者向澄天偉業(300689.SZ)提問,“之前送樣產品測試有結果了麼,有應用在新能源汽車和儲能上麼?”
澄天偉業回覆稱,公司正在積極開拓新能源汽車、光伏逆變、儲能等能源領域相關市場,部分已研發的功率半導體器件目前是給光伏逆變和儲能等場景的頭部企業送樣測試,測試需要匹配終端應用實驗資源,若有重大進展,相關內容將於定期報吿或臨時公吿中及時披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.